01—Abstract
Summary
Summary of the 8-K filed July 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific (BSX) filed an 8-K on July 30, 2024 reporting a routine board change rather than any financial results or operational update.
The Board increased its size from ten to eleven directors and appointed David C. Habiger, effective immediately, to serve until the next annual meeting. He was also named to the Audit Committee and the Executive Compensation and Human Resources Committee.
Habiger's compensation is standard for non-employee directors, prorated through the 2025 annual meeting. It includes a cash retainer of about $94,175a (from a $125,000 annual program amount, payable in cash or an equity alternative) and an equity award of about $161,981 (from a $215,000 annual grant) that vests at the end of his term. The share count will be set on August 1, 2024.
The Company also intends to sign its standard indemnification agreement with him, and he reported no related-party transactions requiring disclosure. For investors, this filing is low-impact.
It contains no guidance, earnings, or change in strategy, and the director's background in technology company leadership and executive compensation oversight adds governance depth. The 8-K itself is not a material event for valuation.
02—Key points
Key Highlights
- Board expanded from 10 to 11 directors with the appointment of David C. Habiger, effective July 30, 2024
- Habiger, CEO of J.D. Power, joins the Audit Committee and the Executive Compensation and Human Resources Committee
- Prorated director compensation: ~$94,175 cash retainer plus ~$161,981 equity award vesting at term end
- Equity grant share count to be determined on August 1, 2024, the first business day of the following month
- Company intends to enter into its standard director indemnification agreement with Habiger
- Habiger reports no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K
- No financial results, guidance, or operational changes are disclosed in this filing
03—Questions
Frequently Asked Questions
Who is David Habiger and why was he appointed?
Habiger has more than 30 years of business leadership experience and is president and CEO of J.D. Power, which he joined in 2018. He previously led several technology companies, including Textura, NDS Group and Sonic Solutions, and sits on the Chicago Federal Reserve Board. The filing does not state a specific reason for the appointment beyond CEO Mike Mahoney's comment that his technology leadership experience will help the company through growth.
Does this filing change Boston Scientific's financial outlook?
No. The 8-K covers a board appointment and related compensation only. It contains no earnings, revenue, guidance, or strategic announcements.
What is the cost to the company of the new director's compensation?
The prorated amounts are about $94,175 in cash (or an equivalent equity alternative) and about $161,981 in equity. These are small relative to the company's overall expenses.
Does the appointment affect board committee composition?
Yes, Habiger was added to the Audit Committee and the Executive Compensation and Human Resources Committee. This adds a director with business and technology-company leadership experience to two key oversight committees.
04—Continue